575452-22-1Relevant articles and documents
4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS
-
Paragraph 00366, (2016/06/28)
Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
Highly hydrophobic isoreticular porous metal-organic frameworks for the capture of harmful volatile organic compounds
Padial, Natalia M.,Quartapelle Procopio, Elsa,Montoro, Carmen,Lopez, Elena,Oltra, J. Enrique,Colombo, Valentina,Maspero, Angelo,Masciocchi, Norberto,Galli, Simona,Senkovska, Irena,Kaskel, Stefan,Barea, Elisa,Navarro, Jorge A. R.
supporting information, p. 8290 - 8294 (2013/09/02)
Tunable hydrophobicity: Efficient air filters for the protection against chemical warfare agents might be achieved by surface functionalization of the pores in robust metal-organic frameworks (MOFs) with fluoroalkyl residues and the precise control of their pore size (see picture). These MOFs capture harmful volatile organic compounds even under extremely moist conditions (80 % relative humidity). Copyright
PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS
-
Page/Page column 104, (2010/08/07)
The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.